283 related articles for article (PubMed ID: 10697073)
1. Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases.
Alexi T; Borlongan CV; Faull RL; Williams CE; Clark RG; Gluckman PD; Hughes PE
Prog Neurobiol; 2000 Apr; 60(5):409-70. PubMed ID: 10697073
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of cannabinoids as neuroprotective agents for damaged cells conducing to movement disorders.
Antonazzo M; Botta M; Bengoetxea H; Ruiz-Ortega JÁ; Morera-Herreras T
Int Rev Neurobiol; 2019; 146():229-257. PubMed ID: 31349929
[TBL] [Abstract][Full Text] [Related]
3. Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease.
Thomas M; Le WD; Jankovic J
Clin Neuropharmacol; 2003; 26(1):18-23. PubMed ID: 12567160
[No Abstract] [Full Text] [Related]
4. Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives.
Schapira AH; Olanow CW; Greenamyre JT; Bezard E
Lancet; 2014 Aug; 384(9942):545-55. PubMed ID: 24954676
[TBL] [Abstract][Full Text] [Related]
5. Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea.
Waters CM; Peck R; Rossor M; Reynolds GP; Hunt SP
Neuroscience; 1988 May; 25(2):419-38. PubMed ID: 2456487
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoids and neuroprotection in basal ganglia disorders.
Sagredo O; García-Arencibia M; de Lago E; Finetti S; Decio A; Fernández-Ruiz J
Mol Neurobiol; 2007 Aug; 36(1):82-91. PubMed ID: 17952653
[TBL] [Abstract][Full Text] [Related]
7. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
Liu B; Dluzen DE
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
[TBL] [Abstract][Full Text] [Related]
8. Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others.
Fernández-Ruiz J; Romero J; Ramos JA
Handb Exp Pharmacol; 2015; 231():233-59. PubMed ID: 26408163
[TBL] [Abstract][Full Text] [Related]
9. Parkinson's disease, Huntington's disease and tardive dyskinesia. Neurochemical pathology and treatment.
Tolosa ES
Minn Med; 1979 Feb; 62(2):101-6. PubMed ID: 155195
[No Abstract] [Full Text] [Related]
10. Beta-adrenergic receptor subtypes in the basal ganglia of patients with Huntington's chorea and Parkinson's disease.
Waeber C; Rigo M; Chinaglia G; Probst A; Palacios JM
Synapse; 1991 Aug; 8(4):270-80. PubMed ID: 1656540
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in the Potential of Cannabinoids for Neuroprotection in Alzheimer's, Parkinson's, and Huntington's Diseases.
Pérez-Olives C; Rivas-Santisteban R; Lillo J; Navarro G; Franco R
Adv Exp Med Biol; 2021; 1264():81-92. PubMed ID: 33332005
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.
Dunkel P; Chai CL; Sperlágh B; Huleatt PB; Mátyus P
Expert Opin Investig Drugs; 2012 Sep; 21(9):1267-308. PubMed ID: 22741814
[TBL] [Abstract][Full Text] [Related]
13. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
Huot P; Lévesque M; Parent A
Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
[TBL] [Abstract][Full Text] [Related]
14. Exploring the potential of natural and synthetic neuroprotective steroids against neurodegenerative disorders: A literature review.
Bansal R; Singh R
Med Res Rev; 2018 Jul; 38(4):1126-1158. PubMed ID: 28697282
[TBL] [Abstract][Full Text] [Related]
15. [Neurodegeneration: aging and dementia. Etiopathogenic role of electron transport disorders. Therapeutic possibilities].
Klivényi P; Vécsei L
Orv Hetil; 1997 Feb; 138(6):331-5. PubMed ID: 9082290
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease.
Alberch J; Pérez-Navarro E; Canals JM
Brain Res Bull; 2002 Apr; 57(6):817-22. PubMed ID: 12031278
[TBL] [Abstract][Full Text] [Related]
17. Immunocytochemical studies of substance P and Met-enkephalin in the basal ganglia and substantia nigra in Huntington's, Parkinson's and Alzheimer's diseases.
Grafe MR; Forno LS; Eng LF
J Neuropathol Exp Neurol; 1985 Jan; 44(1):47-59. PubMed ID: 2578185
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective strategies in Parkinson's disease : an update on progress.
Mandel S; Grünblatt E; Riederer P; Gerlach M; Levites Y; Youdim MB
CNS Drugs; 2003; 17(10):729-62. PubMed ID: 12873156
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in Huntington's disease.
Gutekunst CA; Norflus F; Hersch SM
Curr Opin Neurol; 2000 Aug; 13(4):445-50. PubMed ID: 10970063
[TBL] [Abstract][Full Text] [Related]
20. Chrysin exerts neuroprotective effects against 3-Nitropropionic acid induced behavioral despair-Mitochondrial dysfunction and striatal apoptosis via upregulating Bcl-2 gene and downregulating Bax-Bad genes in male wistar rats.
Thangarajan S; Ramachandran S; Krishnamurthy P
Biomed Pharmacother; 2016 Dec; 84():514-525. PubMed ID: 27690136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
